PI3K/AKT/mTOR通路
癌症研究
细胞生长
弥漫性大B细胞淋巴瘤
细胞凋亡
流式细胞术
细胞周期
下调和上调
淋巴瘤
生物
分子生物学
免疫学
基因
遗传学
作者
Qian Li,Li Bao,Changliang Lu,Jingye Wang,Min Gao,Wei Gao
标识
DOI:10.1038/s41417-020-00267-4
摘要
LINC01857 has been proven to be involved in glioma and breast cancer. However, the biological function of LINC01857 in diffuse large B-cell lymphoma (DLBCL) is poorly investigated. By accessing to the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEX), LINC01857 expression was found upregulated in both DLBCL tissues and cells. Cell proliferation and flow cytometry assays showed that LINC01857 promoted proliferation and cell cycle, but suppressed apoptosis in DLBCL cells. Bioinformatics analysis and luciferase reporter assay confirmed that LINC01857 may serve as a sponge for miR-141-3p and miR-141-3p may target MAP4K4. Mechanically, the regulatory action of miR-141-3p/MAP4K4 on DLBCL cellular behaviors was regulated by LINC01857. In addition, LINC01857 could increase the activity of PI3K/mTOR pathway and facilitate the EMT process in a miR-141-3p-mediated manner in DLBCL. Our data illustrated that the LINC01857/miR-141-3p/MAP4K4 might function as a promising therapeutic avenue for DLBCL treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI